Dextera Surgical Fund Company Profile

Description

Dextera Surgical Inc. designs, manufactures, and markets automated anastomotic systems for use by cardiac surgeons to perform coronary bypass surgery in the United States and internationally. It offers C-Port xA Anastomosis systems to perform an end-to-side distal anastomosis by attaching the end of a bypass graft to a coronary artery downstream of an occlusion or narrowing; C-Port Flex A Anastomosis systems to enable automated anastomoses to be performed as part of CABG procedures; and PAS-Port Proximal Anastomosis systems to perform an end-to-side proximal anastomosis between a saphenous vein and the aorta. The company also offers endoscopic microcutter products comprising MicroCutter XCHANGE 30 for use by thoracic, pediatric, bariatric, colorectal, and general surgeons. In addition, it licenses its intellectual property in the robotics field in diagnostic or therapeutic medical procedures. Cardica, Inc. markets its products through its direct sales force, as well as through independent manufacturers’ representatives and distributors. The company was formerly known as Cardica, Inc. and changed its name to Dextera Surgical Inc. in June 2016. Dextera Surgical Inc. was founded in 1997 and is headquartered in Redwood City, California.